Wealth Alliance Acquires 494 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Wealth Alliance boosted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 19.2% in the 4th quarter, HoldingsChannel reports. The firm owned 3,068 shares of the medical research company’s stock after purchasing an additional 494 shares during the quarter. Wealth Alliance’s holdings in Thermo Fisher Scientific were worth $1,628,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the stock. Coppell Advisory Solutions LLC purchased a new stake in Thermo Fisher Scientific in the 2nd quarter worth $33,000. Live Oak Investment Partners purchased a new position in Thermo Fisher Scientific during the 4th quarter worth $36,000. Tyler Stone Wealth Management bought a new stake in shares of Thermo Fisher Scientific in the 2nd quarter valued at about $37,000. DHJJ Financial Advisors Ltd. purchased a new stake in Thermo Fisher Scientific during the third quarter worth $38,000. Finally, Raleigh Capital Management Inc. raised its position in shares of Thermo Fisher Scientific by 49.1% in the 3rd quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company’s stock worth $41,000 after acquiring an additional 27 shares in the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Stock Performance

TMO stock traded down $2.25 during trading on Tuesday, hitting $555.62. 626,461 shares of the company traded hands, compared to its average volume of 1,533,697. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.75 and a quick ratio of 1.39. Thermo Fisher Scientific Inc. has a 1 year low of $415.60 and a 1 year high of $603.82. The stock’s 50-day simple moving average is $571.79 and its 200 day simple moving average is $526.53. The company has a market cap of $212.09 billion, a PE ratio of 35.97, a P/E/G ratio of 2.38 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.64 by $0.03. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The firm had revenue of $10.89 billion for the quarter, compared to the consensus estimate of $10.73 billion. During the same period in the prior year, the firm posted $5.40 earnings per share. The firm’s quarterly revenue was down 4.9% compared to the same quarter last year. On average, equities analysts expect that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were issued a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 0.28%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date of this dividend was Thursday, March 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.10%.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on TMO shares. Barclays downgraded shares of Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and boosted their target price for the stock from $475.00 to $555.00 in a report on Wednesday, January 24th. Evercore ISI lifted their price target on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an “outperform” rating in a report on Thursday, April 4th. Sanford C. Bernstein reiterated a “market perform” rating on shares of Thermo Fisher Scientific in a report on Monday, January 8th. HSBC started coverage on Thermo Fisher Scientific in a research note on Monday, December 18th. They issued a “buy” rating and a $610.00 price target for the company. Finally, Raymond James upped their price objective on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a report on Thursday, February 1st. Five equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $601.56.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, Director Debora L. Spar sold 164 shares of the firm’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $546.97, for a total value of $89,703.08. Following the transaction, the director now owns 1,207 shares in the company, valued at approximately $660,192.79. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, SVP Michael A. Boxer sold 14,566 shares of the business’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the transaction, the senior vice president now owns 12,901 shares of the company’s stock, valued at approximately $7,250,362. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Debora L. Spar sold 164 shares of the firm’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $546.97, for a total transaction of $89,703.08. Following the sale, the director now owns 1,207 shares of the company’s stock, valued at $660,192.79. The disclosure for this sale can be found here. Insiders have sold 50,277 shares of company stock valued at $28,513,384 over the last ninety days. Insiders own 0.32% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.